User experiencing hair loss on dutasteride; others suggest shedding is normal and to track progress with pictures. Some mention using RU58841 for improvement.
A 22-year-old male experienced hair thinning and found minoxidil ineffective, with blood tests showing deficiencies in zinc, vitamin B12, vitamin D3, and possible hypothyroidism. Another user suggested adding topical finasteride to the regimen, which helped them regrow hair effectively without side effects.
The conversation is about hair loss treatments, specifically asking for updates on verteporfin research following promising results. No specific treatments were discussed in the provided text.
A 23-year-old user shared progress pictures after 12 months of using 1.25mg finasteride daily, reporting reduced hair shedding and considering adding 2.5mg oral minoxidil for further improvement. The discussion includes potential side effects of oral minoxidil, with users advising caution and monitoring under medical supervision.
The user's experience with hair loss, their doctor explaining that they were likely hyper aware of thin spots due to anxiety and an underlying whorl in one area, and providing encouragement for those feeling discouraged. Treatments mentioned include minoxidil and spironolactone.
A user shared their 10.5-month progress using oral finasteride, topical minoxidil, a derma roller, biotin, and Omega 3, despite losing over 150 hairs daily. They also mentioned starting "bald showers" after leg workouts for the last two months.
A user experienced new hair growth and reduced scalp itchiness using a scalp treatment with Neem, Amla, and Rosemary oil. They recommend this natural remedy for those interested in alternative medicine.
Microneedling stimulates hair growth through stem cell activation during wound healing, not just increased blood flow. Other methods like showers or supplements don't replicate this effect.
Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. L'Oreal's study on Stemoxydine 5% claims a 4% increase in hair density after 3 months, but some users question potential bias.
Clascoterone showed promising initial results for hair regrowth but failed to replicate them, leading to disappointment. Users discuss combining it with minoxidil and other treatments, noting its current availability only in lower concentrations.
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
Finasteride showed faster hair regrowth within 3 months, while dutasteride took 8 months but resulted in twice the regrowth. Overall, finasteride had quicker results, but dutasteride had more significant long-term regrowth.
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.
The user showed hair regrowth after two years using finasteride, minoxidil, micro needling, and ketoconazole shampoo, noticing significant improvement around 8-10 months without experiencing shedding. They achieved thicker hair and improved temples, allowing them to style their hair without wearing hats.
The user showed a significant improvement in hair density after four months using finasteride and minoxidil. They also used a micro needle pen, hair care like coconut oil, and improved their diet.
Bhringraj oil showed better hair regrowth results than minoxidil in mice, but its effectiveness in humans is uncertain. Users discussed using bhringraj oil, coconut oil, and microneedling for hair regrowth, with some reporting slow but noticeable improvements.
The user showed 2-3 years of hair regrowth progress using oral finasteride, topical minoxidil, and microneedling. They plan to switch to oral dutasteride and Liposomal Minoxidil Sulfate for better results.
John Cazale's hairline showed strong recession at the temples but maintained solid volume and density, sparking discussion on different hair loss patterns and the importance of overall hair density. Treatments like Minoxidil and Spironolactone were mentioned as potential factors in maintaining hair, though genetics and styling were also considered significant.
Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.
Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.
Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.
The user showed progress in hair regrowth using topical Minoxidil, oral Finasteride, and derma rolling with tretinoin. They seek advice on achieving Norwood 1 and the number of grafts needed for hairline restoration.
Minoxidil initially showed great results for hair loss but plateaued, leading to the addition of finasteride and dutasteride. The user is considering restarting minoxidil and is concerned about its long-term effects on skin.
A treatment showed a 20% hair density increase in weeks, with nearly a third of participants experiencing significant results, while questions remain about its long-term efficacy and effectiveness across different scalp areas. There is interest in combining it with finasteride and minoxidil for potentially better outcomes.
ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.
Minoxidil 0.5% MMP® showed better results in parietal-vertex regions for less advanced female pattern hair loss compared to Minoxidil 5%. MMP® with Minoxidil can improve the quality of life for these patients.
TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.
Pyrilutamide phase 3 results showed little to no significant hair regrowth, but may be sufficient for maintaining current hair density. The user is unsure due to lack of recent discussions on pyrilutamide.